Skip to main content

Main navigation

  • Expertise
  • Publications & Insights
  • People
  • Careers

Secondary navigation

  • Value added services
  • CSR
  • About us

SearchSearch results for: “免费vps搭建网站,VPS 独立IP 搭建phpwind 教程,国内月付vps,国外vps排行榜,VPS性能测试技巧,等欢迎访问豌豆Ai站群搜索引擎系统官方网站:www.wd.chat”

68 results

First trip around the sun: FSR – one year in review

The Foreign Subsidies Regulation has celebrated one year of its application. Time for companies to take stock of the lessons learnt from key developments of this first year. However, ambiguities remain and more is yet to come. Watch this space!

Commission takes labour market enforcement to the next level

Employers beware: the European Commission is strengthening its actions against anticompetitive practices in labour markets. In its recent Competition Policy Brief it takes a tough stance. Companies are well-advised to review their employment practices.

Google Android-ruling: Commission flunks AEC test once again

The AEC test has likely assumed mythic status at the European Commission with the EU courts striking down its AEC analysis for a third time. Nevertheless, the Commission seems on the right track to tackling abuse of dominance in the digital sector.

Killing three birds with one stone: Illumina wins Article 22 battle

The ECJ wrote the epilogue to the Illumina/Grail saga, overturning the EC’s novel ‘Article 22’ approach. It is now clear that the EC cannot accept referral requests to review transactions that fall below the thresholds of national merger control regimes.

Digital Markets Act: “with great power must come great responsibility”

The countdown is on for digital giants. The entry into force of the Digital Markets Act (DMA) on 1 November 2022 triggered a to do list for potential gatekeepers with 2 May 2023 as the next key date to keep in mind: see our DMA infographic.

The Commission’s ‘killer’ pharma campaign: reason to complain?

The European Commission is on the prowl in the pharma sector. Recent cases on alleged disparagement and pipeline drugs-killings show that it is not afraid to show its teeth and, ultimately, bite.

Competition law in 2024: putting theory into practice

2023 marked the near finale of the European Commission’s overhaul of its competition policy, leaving only a few loose ends to tie up in 2024/2025. It is now time to watch theory be put into practice by the competition authorities and at the courts.

Digital antitrust conduct: too elusive to catch?

The ink on the Digital Market Act has barely dried, but fast-evolving digital developments already have competition authorities calling for new tools. Is Big Tech not kept in check by the DMA, the antitrust rules and the EU Merger Regulation after all?

Competition law developments in 2022

While 2022 revolved around new and improved regulatory tools, the focus in 2023 will be on putting these tools to use. More merger-related obligations, digital sector scrutiny and clarity on competition-law and consumer-law aspects is imminent.

C'est le ton qui fait la musique – The end of employer copyrights?

The CJEU decision in the National Orchestra of Belgium decision shakes up employer copyright in the Netherlands. With new consent and compensation requirements, are your employment contracts still airtight? Discover the implications of the decision here.

The long and (un)winding road of ‘killer acquisition’ Illumina/Grail

Crystal ball gazing into prospective innovation rat races when assessing vertical mergers may soon be all in a day’s work for the European Commission. Innovation was a recurring theme in the Commission’s handling of the Illumina/Grail deal.

If you have nothing nice to say…Teva fined heavily for abusive conduct

Dominant pharma companies had better watch their words and use the patent system wisely. Pharma company Teva was fined EUR 462.6 million for disparagement and ‘divisional gaming’ to delay market entry and hinder the uptake of a competing drug.

The ECJ’s ruling in Servier: Never Settle For Less

Patent settlement agreements between originator pharmaceutical companies and generics manufacturers are a risky business. Originator medicine company Servier and five generic companies rolled the dice and the ECJ largely confirmed their antitrust fines.

Tom Verdonk

Associate Amsterdam

Pagination

  • Previous page
  • Page 1
  • Page 2
  • Page 3
  • Current page 4
Reset filters
Date
Content type
  • Article (66)
  • Matter (1)
  • People (1)
Expertise
  • (-) EU and Competition Law (68)
  • Audit Firms and Accountancy (2)
  • Banking and Finance (6)
  • Capital Markets (1)
  • Compliance, Sanctions and Risk (7)
  • Corporate and M&A (17)
  • Corporate Investigations (8)
  • Criminal Law and Enforcement (8)
  • Employment, Benefits and Pensions (2)
  • Energy, Industry and Climate (14)
  • Environment and Planning (14)
  • ESG & Sustainability (6)
  • Financial Regulation (1)
  • Healthcare and Life Sciences (15)
  • Infrastructure and Mobility (7)
  • Insurance (1)
  • Intellectual Property (43)
  • Investment Funds (2)
  • Litigation and Arbitration (17)
  • Mass Litigation (5)
  • Privacy and Data Protection (21)
  • Private Equity (4)
  • Procurement Law (3)
  • Public Law (26)
  • Real Estate (9)
  • Restructuring and Insolvency (5)
  • Sports (1)
  • Tax (6)
  • Tech (26)
  • Technology, Media and Telecommunications (41)
  • Unfair Competition and Consumer Protection (13)
Jurisdiction
  • BE Law (8)
  • EU Law (59)
  • LU Law (6)
  • NL Law (44)
Language
  • Dutch (3)
  • English (65)

Footer main navigation

  • Expertise
  • Publications & Insights
  • People
  • Careers
© 2025 Stibbe

Footer navigation

  • Contact
  • Disclaimer
  • General Conditions
  • Register of legal practice areas
  • Privacy and Cookie Policy
  • Important Information